October 9, 2013

Lucinda K. Porters’ newest book “Hepatitis C Treatment One Day at a Time” is a must have companion for anyone getting ready to start treatment for hepatitis C. This is not just written by Ms. Porter a Registered Nurse, but as someone who has been through hepatitis C treatment herself. That is what makes this book so unique.

'”Hepatitis C Treatment One Day at a Time'’ begins with advice on how to prepare for treatment then continues on to walk the reader through each day from beginning to end whether it be 12, 16, 24 or 48 weeks of treatment. Each day offers an inspirational quote, words of encouragement as well as tips on how to get through the day.

I recommend this book not only to the patients themselves but to their family members and friends as well. It is so hard to understand what one goes through during treatment unless one has been through it themself. Yet this book will not not only help the patient through treatment, but at the same time help their family and friends understand the daily struggles that one on treatment has to deal with.

Thank you so much Lucinda for writing this book which will help so many get through treatment a little easier and for all that you do for the HCV community.

Results: Baseline characteristics were well-balanced in the DCV 12-week (N=50), DCV 16-week (N=50) and placebo (N=51) arms; more patients with GT3 (18/80, 22.5%) than GT2 (1/71, 1.4%) were cirrhotic. 78%-88% of DCV recipients achieved PDR. SVR24 rates were higher in GT2 than GT3 with all regimens; within each genotype, SVR24 rates were similar in DCV arms and higher than placebo/peg-alfa/RBV. In DCV arms, one GT2 and 12 GT3 patients relapsed. In GT3, relapse was higher among cirrhotics (3/7, 43%) than non-cirrhotics (3/19, 16%) in the 12-week arm but similar in the 16-week arm (1/4, 25% vs 5/20, 25%). There were 7 on-treatment serious AEs (DCV, 4; placebo, 3); no deaths. AEs were typical of those associated with peg-alfa/RBV.

Conclusion: Shorter treatment duration (12 or 16 weeks) with DCV/peg-alfa/RBV demonstrated higher SVR rates than 24 weeks of peg-alfa/RBV in patients with GT2 or GT3 infection, with higher SVR rates in GT2 with all regimens. These results support further evaluation of DCV-containing regimens for different HCV genotypes.

FAIR USE NOTICE:

This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. It is being made available in an effort to advance the understanding of Hepatitis C, New hepatitis c drugs, Related clinical trials and ongoing research, HIV/HCV coinfection, HIV/AIDS, Other factors of liver disease, and so on. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.

The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute medical or health related advice.